India, Oct. 1 -- Biocon Biologics Ltd. announced a settlement and license agreement with Amgen Inc., clearing the way to commercialize its denosumab biosimilars Bosaya™ and Aukelso™ in the United States starting October 1, 2025.
The settlement resolves pending patent litigation in the U.S. District Court for New Jersey. Both products, approved by the U.S. FDA in September 2025 with provisional interchangeability designation, are biosimilars to Amgen's Prolia® and Xgeva®, used for osteoporosis and cancer-related bone conditions.
Shreehas Tambe, CEO & MD, said the launch expands Biocon Biologics' oncology and bone health portfolio, reinforcing the company's global leadership in biosimilars.
Published by HT Digital Conte...